Indivior Pharmaceuticals, Inc. Common Stock INDV

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

• GlobeNewswire Inc. 2 oct

  Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

  The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

  

• GlobeNewswire Inc. 30 sept

  Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

  

• Zacks Investment Research 2 sept

  Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

  Indivior Pharmaceuticals beat Q2 2026 earnings estimates with adjusted EPS of $1.15 (vs. $0.97 consensus) and revenues of $343 million (vs. $308 million consensus), driven by strong Sublocade performance. The company raised its full-year 2026 guidance and improved profitability through cost management. Despite these positive results, shares have declined 5.3% since the earnings report, underperforming the S&P 500. The stock holds a Zacks Rank #2 (Buy) with upward estimate revisions.

  

• The Motley Fool 3 ago

  Why Supernus Pharmaceuticals Stock Topped the Market Today

  Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

  

• GlobeNewswire Inc. 23 jul

  Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

  Indivior Pharmaceuticals announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team members. The company will discuss its performance as a leader in long-acting injectable treatments for opioid use disorder.